SENS-401

Phase 2Small molecule

SSensorion

SENS-401 is one of 61 small molecule programs targeting Sudden Sensorineural Hearing Loss. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sudden Sensorineural Hearing LossActive, not recruiting

OtotoxicityActive, not recruiting

Hearing LossCompleted

Sudden Sensorineural Hearing LossPhase 2/Phase 3

Active, not recruiting

OtotoxicityPhase 2

Active, not recruiting

Hearing LossPhase 2

Completed

Competition

Competitive Landscape

46 competitors in Hearing Loss

#DrugCompanyPhaseTrials

Cymbalta

Alnylam Pharmaceuticals

Approved

1 2

Medrol

Pfizer

Approved

1 3

Decadron

AAspen Global Incorporated

Approved

4 4

Plaquenil

Alnylam Pharmaceuticals

Cipro

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 7

Osmitrol

BB. Braun Medical Inc.

Approved

—8

Kenalog

BBausch Health Americas, Inc.

Approved

—9

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Zonegran

AAzurity Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sudden Sensorineural Hearing Loss1 trial

Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Completed·SSensorion·Phase 2/3·NCT03603314·115 enrolled

Hearing Loss1 trial

A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Completed·SSensorion·Phase 2·NCT05628233·48 enrolled

Unspecified2 trials

Evaluation of the Presence of SENS-401 in the Perilymph

Completed·SSensorion·Phase 2·NCT05258773·28 enrolled

A Study of SENS 401 in Healthy Subjects

Completed·SSimbec Research·Phase 1·NCT03071003·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SENS-401. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SENS-401 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SENS-401. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sensorion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSensorion

SENS-401

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sudden Sensorineural Hearing Loss1 trial

Hearing Loss1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News